MedTrace Logo

Observation of Patients With Metastatic Colorectal Cancer Starting Chemotherapy Combined With Bevacizumab (Avastin)

NCT02612077 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 765

Last updated 2016-03-11

Study results available
· View outcomes & findings →

Summary

This is a longitudinal, multicenter, prospective, pharmacoepidemiological study to evaluate progression free survival (PFS) in a real-life setting in participants with metastatic colorectal cancer (mCRC) starting chemotherapy combined with bevacizumab.

Conditions

Interventions

OTHER

Observational Chemotherapy

No intervention - Observational standard practice chemotherapy

DRUG

Concomitant Bevacizumab

No intervention - Observational concomitant bevacizumab

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02612077 on ClinicalTrials.gov